Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Phase 3Active, not recruiting
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of BFB759 in hidradenitis suppurativa (HS). Started Nov 2025; status: active, not recruiting.
02
Drugs
BFB759
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07287644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287644.